Camera company’s finances under higher scrutiny.
President Trump’s Administration announced on Tuesday that the proposed deal that would resurrect Kodak as a pharmaceutical company based in the United States would be put on hold. Higher scrutiny of the company’s finances resulted in the $765 million taxpayer-funded deal to wait until an investigation could take place.
The president didn’t have much to say about the deal beyond the optics of the branding saying, “It’s a great name when you think of it. Such a great name. It was one of the great brands in the world.” Peter Navarro, a trade advisor in the administration expressed his frustration that the plan wasn’t moving forward and that the U.S. “must redouble efforts to bring our pharma manufacturing home.”
As the Lord Leads, Pray with Us…
- That God would lead the administration to improve the pharmaceutical industry.
- For President Trump to have wisdom on how to manage this deal.
- That Mr. Navarro would effectively advise the president.
Sources: NPR, CNN, Fox News
